Pair page
Liraglutide with Mazdutide
Mechanism-tag overlap and published literature for Liraglutide and Mazdutide, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
Liraglutide unique
daily-glp-1-receptor-agonist
Shared
incretin-peptide
Mazdutide unique
dual-glp-1-glucagon-receptor-agonist
Quick facts
Liraglutide
RouteSubQ once daily
Half-life~13 hours
FDA statusApproved (T2D 2010, obesity 2014, peds 2019)
WADANot listed
Mazdutide
RouteSubQ once weekly
Half-lifeWeekly dosing compatible
FDA statusNot approved
WADANot listed
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2022 | Liraglutide | Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2022;327(2):138-150. PMID: 35015037. (Head-to-head sema vs lira.) PMID 35015037 | human trial |
| 2020 | Liraglutide | Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, Mastrandrea LD, Prabhu N, Arslanian S; NN8022-4180 Trial Investigators. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020;382(22):2117-2128. PMID: 32320651. PMID 32320651 | human trial |
| 2020 | Liraglutide | Verma S, Bain SC, Honoré JB, et al. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure (LEADER substudy). J Am Coll Cardiol. 2020;75(13):1505-1517. PMID: 32164886. PMID 32164886 | human trial |
| 2017 | Liraglutide | Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(9):839-848. PMID: 28854085. PMID 28854085 | human trial |
| 2016 | Liraglutide | Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 201… PMID 27295427 | human trial |
| 2015 | Liraglutide | Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015… PMID 26132939 | human trial |
| 2015 | Liraglutide | Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, Andreasen AH, Jensen CB, DeFronzo RA; NN8022-1922 Study Group. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015;314(7):687-699. P… PMID 26284720 | human trial |
| 2013 | Liraglutide | Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443-1451. PMID: 23812094. PMID 23812094 | human trial |
| 2009 | Liraglutide | Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606-1616. PMID: 19853906. PMID 19853906 | human trial |
| — | Liraglutide | NICE. Liraglutide for the treatment of type 2 diabetes mellitus and weight management. UK National Institute for Health and Care Excellence guidance documents. | human study |
| 2014 | Liraglutide | FDA. Saxenda (liraglutide) prescribing information. December 2014, updated periodically. | regulatory / registry |
| 2010 | Liraglutide | FDA. Victoza (liraglutide) prescribing information. January 2010, updated periodically. | regulatory / registry |
| 2025 | Mazdutide | Ji L, Jiang H, Bi Y, Li H, Tian J, Liu D, et al; GLORY-1 Investigators. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025;392(22):2215-2225. PMID: 40421736. DOI: 10.1056/NEJMoa2411528. (Pivotal GLORY-1 Phase 3 publication, May 2025.) PMID 40421736 | human trial, Phase 3 |
| 2025 | Mazdutide | Ji L, Qian L, et al; DREAMS-1 Investigators. Mazdutide in Chinese adults with untreated type 2 diabetes: DREAMS-1 Phase 3 trial. Nature. 2025. (Accelerated Article Preview publication, late 2025; part of back-to-back Nature release.) | human trial, Phase 3 |
| 2025 | Mazdutide | Ji L, et al; DREAMS-2 Investigators. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes inadequately controlled on oral medication: DREAMS-2 Phase 3 trial. Nature. 2025. (Back-to-back with DREAMS-1.) | human trial, Phase 3 |
| 2025 | Mazdutide | Innovent Biologics press release. Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature. November 2025. | human trial, Phase 3 |
| 2025 | Mazdutide | BioSpace press release. Second Head-to-head Phase 3 Study of Mazdutide versus Semaglutide Completes First Participant Dosing in Adults in China with Overweight or Obesity Accompanied Fatty Liver Disease (GLORY-3). May 15, 2025. | human trial, Phase 3 |
| 2018 | Mazdutide | Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet. 2018;391(10… PMID 29945726 | human trial, Phase 2 |
| 2022 | Mazdutide | Ji L, Gao L, Jiang H, Yang J, Yu L, Wen J, et al. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinical… PMID 36337827 | human trial, Phase 1 |
| 2022 | Mazdutide | Jiang H, Pang S, Zhang Y, Yu T, Liu M, Deng H, et al. A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nat Commun. 2022;13(1):3613. PMID: 35750890. (Phase 1b / dose… PMID 35750890 | human trial, Phase 1 |
| 2025 | Mazdutide | Innovent Biologics press release. Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes. September 19, 2025. | human study |
| 2017 | Mazdutide | Sánchez-Garrido MA, Brandt SJ, Clemmensen C, Müller TD, DiMarchi RD, Tschöp MH. GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia. 2017;60(10):1851-1861. PMID: 28733905. (Class review.) PMID 28733905 | human study |
| 2009 | Mazdutide | Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes. 2009;58(10):2258-2266. PMID: 19602537. (Preclinical proof-of-concept for the dual-agonist class.) PMID 19602537 | preclinical, in vivo |
| 2018 | Mazdutide | Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. PMID: 29617641. (GLP-1 mechanism framework.) PMID 29617641 | research article |
Related pair pages
More research context
Frequently asked
Have Liraglutide and Mazdutide been studied together?
No co-administration studies between Liraglutide and Mazdutide are catalogued on Kalios. The pair page lists only the individual published literature for each compound and any shared mechanism tags.
What mechanisms do Liraglutide and Mazdutide share?
Liraglutide and Mazdutide share these mechanism tags on their Kalios profiles: incretin-peptide. Tags are descriptive and verbatim from each compound profile — not an inference of combined effect.
What is the FDA status of Liraglutide and Mazdutide?
Liraglutide: Approved (T2D 2010, obesity 2014, peds 2019). Mazdutide: Not approved. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Liraglutide and Mazdutide?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Liraglutide profile and the Mazdutide profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026